Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Public ClinicalTrials.gov record NCT00819091. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
Study identification
- NCT ID
- NCT00819091
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 245 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2008 (Type not available)
- Primary completion
- Jan 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 27, 2014
Started 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.35.10002 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1218.35.10001 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.35.10016 Boehringer Ingelheim Investigational Site | National City | California | — | — |
| 1218.35.10017 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1218.35.10021 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1218.35.10013 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.35.10015 Boehringer Ingelheim Investigational Site | Flint | Michigan | — | — |
| 1218.35.10018 Boehringer Ingelheim Investigational Site | Asheville | North Carolina | — | — |
| 1218.35.10004 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1218.35.10005 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 1218.35.10020 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1218.35.10009 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.35.10019 Boehringer Ingelheim Investigational Site | Sugar Land | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00819091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2014 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00819091 live on ClinicalTrials.gov.